Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Rituximab + Lenalidomide in Untreated FL and MZL
NCT02532257Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2016
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 24 months. Started Apr 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02532257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532257.